Tuberculosis transporter Rv1250 linked to broad antibiotic efflux

Drug-resistant Mycobacterium tuberculosis remains one of the leading causes of global mortality, and scientists are working to understand the bacterial tricks that make treatment fail. Known mechanisms include slow uptake of drugs, cell wall impermeability and active efflux systems that push antibiotics away from their targets. In new work led by Anindya S. Ghosh, researchers investigated a specific transporter from M. tuberculosis called Rv1250, described as a probable MFS-type transporter. The team explored whether Rv1250 could help cells resist a wide range of antibiotics by exporting them out of the bacterial cell. To study the gene’s effects, the researchers introduced rv1250 into other bacterial hosts and compared how these modified cells behaved under antibiotic stress. They also looked at how expression of rv1250 influenced biofilm formation and the ability of bacteria to survive inside host immune cells. By focusing on Rv1250, the study set out to clarify whether this putative transporter contributes to intrinsic drug tolerance and could therefore play a role in treatment failure of anti-tubercular medications.

The experiments examined multiple outcomes after expression of the MFS-type transporter. In trans, the expression of rv1250 decreased the susceptibility of host cells to several structurally unrelated antibiotics, ranging from fluoroquinolones to aminoglycosides, beta-lactams, and anti-tubercular drugs, indicating a broad influence on drug tolerance. The researchers tested different host systems, including E. coli and Mycobacterium smegmatis, and observed that Rv1250 influenced extrusion of multiple structurally unrelated classes of drugs. Direct measures of drug movement showed increased efflux: host cells expressing rv1250 conferred a lower level of antibiotic accumulation and revealed increased efflux of EtBr, norfloxacin, and Bocillin FL. Beyond drug transport, expression of rv1250 enhanced biofilm formation in E. coli and Mycobacterium smegmatis. The transporter also facilitated the survival of M. smegmatis cells inside the macrophage during antibiotic stress. Together, these results point to Rv1250 functioning as an efflux pump that can reduce intracellular antibiotic levels across diverse compounds.

These findings suggest that Rv1250 of Mycobacterium tuberculosis might help bacteria survive antimicrobial stress by actively exporting a wide range of drugs and promoting protective behaviours like biofilm formation. Because efflux pumps are considered an emerging cause for the failure of anti-tubercular medications and treatment, identifying a specific transporter with such broad activity is important. The fact that rv1250 expression lowered accumulation of EtBr, norfloxacin, and Bocillin FL and decreased susceptibility to fluoroquinolones, aminoglycosides, beta-lactams and anti-tubercular drugs implies a potential role in intrinsic drug tolerance. For researchers and clinicians, Rv1250 represents a candidate for further study: understanding its mechanism, its natural expression in M. tuberculosis infections, and whether blocking its activity alters treatment outcomes will be key next steps. While this work documents a plausible efflux function in model systems, translating that knowledge into interventions will require additional studies directly in M. tuberculosis and clinical contexts.